Clinical Trials in Tennessee

Showing 18721-18740 of 20,239 trials

PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca

NCT00467116

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and help kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Cetuximab may also stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Gemcitabine and cetuximab may make tumor cells more sensitive to radiation therapy. Giving gemcitabine together with cetuximab and radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine when given together with cetuximab and radiation therapy in treating patients with locally advanced pancreatic cancer that cannot be removed by surgery.

Pancreatic Cancer

Vanderbilt-Ingram Cancer Center9 participantsStarted Oct 2005

Nashville, Tennessee, United States

COMPLETEDPhase 129 miles

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

NCT00595686

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Hematologic Neoplasms

Esanex Inc.25 participantsStarted Jan 2008

Augusta, Georgia, United States • Chapel Hill, North Carolina, United States • Pittsburgh, Pennsylvania, United States +1 more locations

PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Find Trials by Condition in Tennessee

Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

Paracor Ventricular Support System (PVSS) for Patients With Heart Failure

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS

Breast Cancer Screening Via Computer V. Phone

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)